Pay attention to the following story unfolding beneath the surface on Wall Street
While everyone is busy with the Nasdaq and debating whether there will be an attack or not
Larry Robbins, one of the prominent healthcare investors on Wall Street, is returning to the surgical center company he previously exited, with a holding 1.8 times larger than anything he held before
$SGRY So what exactly is happening here?
It all starts with a report we received a few days ago, almost in real-time from our systems,
Glenview, Robbins' fund, holds 7,023,338 shares of Surgery Partners, 5.4% of the company, valued at approximately $94,183,000 according to the close on October 6, the day the threshold was crossed.
Did you notice what happened here?
A turnaround.
At the end of 2025, Glenview held 3,858,088 shares (approximately $59,607,000),
By March 2026, 1,800,000 remained (approximately $21,456,000),
By June, the stock no longer appeared, the position was closed.
But within approximately 100 days, he bought shares, and the position returned in a big way.
And the timing?
On August 18, director Theresa DeLuca made an insider purchase of 11,250 shares at an average price of $14.33, approximately $161,212 from her personal funds.
This was her first insider purchase since November 2022.
The purchase was made on the open market, at market price.
And who exactly is Surgery Partners and what do they do?
It deals with outpatient surgeries, day surgery centers, and surgical hospitals, with 178 facilities in 30 US states.
Look how this story unfolded, without anyone even noticing...
On October 29, 2025, the stock reached a peak of $23.44.
On March 4, after the annual report, RBC cut its target from $31 to $20, one of five investment firms that cut targets within three days.
On June 30, according to the quarterly report, Glenview no longer held the stock, the position was closed.
And then:
On August 10, the company reported its quarterly results, revenue at existing facilities increased by 5.0%, and the company reaffirmed its guidance for the year.
A week later, on August 18, DeLuca's insider purchase, at $14.33.
And on October 6, Glenview already crossed 5%, with the stock at $13.41, approximately 43% below its peak.
The market saw target cuts and sold, Robbins, who had already exited the stock, saw the numbers in the new report and returned with 3.9 times what he had in March.
Meanwhile, the company is focusing on the shift of surgeries from hospitals to day centers; according to TD Cowen, the field is still far from saturation, and insurance companies are approving more and more outpatient surgeries.
When a fund manager who built his name on hospitals returns to a biotechnology stock he exited, just a few weeks after an insider purchase by a senior executive at the company, we add it to our watchlist.